

Pierre Koch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9393383/publications.pdf>

Version: 2024-02-01

46
papers

1,018
citations

471371

17
h-index

434063

31
g-index

49
all docs

49
docs citations

49
times ranked

1385
citing authors

#	ARTICLE	IF	CITATIONS
1	The Cysteinome of Protein Kinases as a Target in Drug Development. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 4372-4385.	7.2	173
2	Inhibitors of c-Jun N-Terminal Kinases: An Update. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 72-95.	2.9	81
3	Targeting the Gatekeeper MET146 of C-Jun N-Terminal Kinase 3 Induces a Bivalent Halogen/Chalcogen Bond. <i>Journal of the American Chemical Society</i> , 2015, 137, 14640-14652.	6.6	73
4	Targeting the Ribose and Phosphate Binding Site of p38 Mitogen-Activated Protein (MAP) Kinase: Synthesis and Biological Testing of 2-Alkylsulfanyl-, 4(5)-Aryl-, 5(4)-Heteroaryl-Substituted Imidazoles. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5630-5640.	2.9	66
5	c-Jun N-terminal kinase inhibitors: a patent review (2010 – 2014). <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 849-872.	2.4	47
6	Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 594-607.	2.9	46
7	Tetra-Substituted Pyridinylimidazoles As Dual Inhibitors of p38 Mitogen-Activated Protein Kinase and c-Jun N-Terminal Kinase 3 for Potential Treatment of Neurodegenerative Diseases. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 443-456.	2.9	43
8	SK4 channels modulate Ca ²⁺ signalling and cell cycle progression in murine breast cancer. <i>Molecular Oncology</i> , 2017, 11, 1172-1188.	2.1	43
9	Tri- and tetrasubstituted imidazoles as p38 mitogen-activated protein kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 6671-6675.	1.0	36
10	Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 437-439.	1.5	33
11	Role of the Hydrogen Bonding Heteroatom-Lys53 Interaction between the p38 Mitogen-Activated Protein (MAP) Kinase and Pyridinyl-Substituted 5-Membered Heterocyclic Ring Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2613-2617.	2.9	32
12	Pyridinylquinoxalines and Pyridinylpyridopyrazines as Lead Compounds for Novel p38 Mitogen-Activated Protein Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1128-1137.	2.9	28
13	Pyridinylimidazoles as dual glycogen synthase kinase 3/p38 mitogen-activated protein kinase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 175, 309-329.	2.6	26
14	Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38 Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3. <i>ACS Omega</i> , 2018, 3, 7809-7831.	1.6	24
15	An Efficient Synthesis of the Protected Carbohydrate Moiety of Brasilicardin A. <i>Organic Letters</i> , 2011, 13, 3710-3713.	2.4	23
16	Controlling the Covalent Reactivity of a Kinase Inhibitor with Light. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 20178-20183.	7.2	23
17	Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38 mitogen-activated protein kinase. <i>Analytical Biochemistry</i> , 2016, 503, 28-40.	1.1	22
18	Synthesis and Bioactivity of a Brasilicardin A Analogue Featuring a Simplified Core. <i>Organic Letters</i> , 2015, 17, 3608-3611.	2.4	17

#	ARTICLE	IF	CITATIONS
19	Unexpected Reaction of 2-Alkylsulfanylimidazoles to Imidazol-2-ones: Pyridinylimidazol-2-ones as Novel Potent p38 β Mitogen-Activated Protein Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4798-4802.	2.9	15
20	High-Quality Draft Genome Sequence of the Actinobacterium <i>Nocardia terpenica</i> IFM 0406, Producer of the Immunosuppressant Brasilicardins, Using Illumina and PacBio Technologies. <i>Genome Announcements</i> , 2016, 4, .	0.8	14
21	Pyridinylimidazoles as GSK3 β Inhibitors: The Impact of Tautomerism on Compound Activity via Water Networks. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1407-1414.	1.3	12
22	Genetic Engineering in Combination with Semi α Synthesis Leads to a New Route for Gram α Scale Production of the Immunosuppressive Natural Product Brasilicardin α ...A. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 13536-13541.	7.2	12
23	Design, Synthesis and Biological Evaluation of 7-Chloro-9H-pyrimido[4,5-b]indole-based Glycogen Synthase Kinase-3 β Inhibitors. <i>Molecules</i> , 2019, 24, 2331.	1.7	11
24	From 2-Alkylsulfanylimidazoles to 2-Alkylimidazoles: An Approach towards Metabolically More Stable p38 β MAP Kinase Inhibitors. <i>Molecules</i> , 2017, 22, 1729.	1.7	10
25	The Symmetric Tetravalent Sulfhydryl-Specific Linker NATBA Facilitates a Combinatorial α Tool Kit α Strategy for Phage Display-Based Selection of Functionalized Bicyclic Peptides. <i>ACS Omega</i> , 2018, 3, 12361-12368.	1.6	10
26	Structure-Based Design of High-Affinity Fluorescent Probes for the Neuropeptide YY ₁ Receptor. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4832-4853.	2.9	10
27	Fluorescence polarization-based competition binding assay for c-Jun N-terminal kinases 1 and 2. <i>Analytical Biochemistry</i> , 2017, 532, 26-28.	1.1	9
28	2-Alkylsulfanyl α (5) α heteroarylimidazoles: An Overview on Synthetic Strategies and Biological Activity. <i>Archiv Der Pharmazie</i> , 2017, 350, 1700258.	2.1	9
29	Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung. <i>Angewandte Chemie</i> , 2018, 130, 4456-4470.	1.6	9
30	Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3 β Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1283-1301.	2.9	9
31	Switching Between Bicyclic and Linear Peptides α ” The Sulfhydryl-Specific Linker TPSMB Enables Reversible Cyclization of Peptides. <i>Frontiers in Chemistry</i> , 2018, 6, 484.	1.8	7
32	Design and Synthesis of Highly Selective Brain Penetrant p38 β Mitogen-Activated Protein Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1225-1242.	2.9	7
33	A Diverse and Versatile Regiospecific Synthesis of Tetrasubstituted Alkylsulfanylimidazoles as p38 β Mitogen-Activated Protein Kinase Inhibitors. <i>Molecules</i> , 2018, 23, 221.	1.7	6
34	Discovery and Evaluation of Enantiopure 9H-pyrimido[4,5-b]indoles as Nanomolar GSK-3 β Inhibitors with Improved Metabolic Stability. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7823.	1.8	6
35	An optimized and versatile synthesis to pyridinylimidazole-type p38 β mitogen activated protein kinase inhibitors. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 10699-10704.	1.5	4
36	Inhibitors of c-Jun N-Terminal Kinase 3. <i>Topics in Medicinal Chemistry</i> , 2020, , 203-224.	0.4	2

